B
BIOMERICA INC
BMRACIK 0000073290NasdaqNon-AcceleratedSmaller ReportingIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends May 31
Period
FY 2025
Revenue
$5.31M
Net Income
$-4.97M
Total Assets
$5.95M
Equity
$4.11M
Shares Out
3.09M
Op. Cash Flow
$-3.84M
Business
BIOMERICA INC is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products. It offers diagnostic test kits and rapid point-of-care and home-use tests that analyze blood, urine, nasal or fecal specimens to detect bacteria, hormones, antibodies, antigens and other substances, including products such as inFoods® IBS and hp+detect™. The company operates research and development, manufacturing/assembly and contract manufacturing capabilities and maintains regulatory, sales and quality divisions. It sells worldwide to clinical laboratories, physicians’ offices, distributors, retail pharmacies and e-commerce channels.
Summary from filing dated 2025-08-29
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-05-31 | FY 2024 2024-05-31 | FY 2023 2023-05-31 | FY 2022 2022-05-31 | FY 2021 2021-05-31 |
|---|---|---|---|---|---|---|
| Net sales | 5 | 5 | 5 | 19 | 7 | |
| Cost of sales | −5 | −5 | −5 | −16 | −7 | |
| Gross profit | 498,000 | 611,000 | 446,000 | 3 | 366,285 | |
| Selling, general and administrative | 5 | 5 | 6 | 6 | 6 | |
| Research and development | 1 | 1 | 2 | 2 | 2 | |
| Total operating expense | 6 | 7 | 8 | 8 | 8 | |
| Loss from operations | −5 | −6 | −7 | −5 | −7 | |
| Dividend and interest income | 165,000 | 431,000 | 133,000 | — | — | |
| Total other income | 165,000 | 431,000 | 134,000 | 27,000 | 66,496 | |
| Loss before income taxes | −5 | −6 | −7 | −5 | −7 | |
| Provision for income taxes | −1,000 | −42,000 | −51,000 | −24,000 | −13,000 | |
| Net loss | −5 | −6 | −7 | −5 | −7 | |
| Basic net loss per common share | −2.16 | −2.84 | −0.5 | −0.36 | −0.62 | |
| Diluted net loss per common share | −2.16 | −2.84 | −0.5 | −0.36 | −0.62 | |
| Basic | 2 | 2 | 14 | 13 | 12 | |
| Diluted | 2 | 2 | 14 | 13 | 12 | |
| Foreign currency translation | −3,000 | 8,000 | −36,000 | −26,000 | −8,115 | |
| Comprehensive loss | −5 | −6 | −7 | −5 | −7 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-05-31 | FY 2024 2024-05-31 | FY 2023 2023-05-31 | FY 2022 2022-05-31 | FY 2021 2021-05-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 2 | 4 | 10 | 6 | 4 | |
| Accounts receivable, net | 731,000 | 947,000 | 722,000 | 774,000 | 1 | |
| Inventories, net | 1 | 2 | 2 | 2 | 3 | |
| Prepaid expenses and other | 255,000 | 238,000 | 300,000 | 320,000 | 370,290 | |
| Total current assets | 5 | 8 | 13 | 9 | 9 | |
| Property and equipment, net of accumulated depreciation and amortization | 135,000 | 201,000 | 213,000 | 214,000 | 311,000 | |
| Right-of-use assets, net of accumulated amortization of $1,223,000 and $910,000 as of May 31, 2025 and 2024, respectively | 429,000 | 742,000 | 1 | 1 | 2 | |
| Investments | 165,000 | 165,000 | 165,000 | 165,000 | 165,324 | |
| Intangible assets, net of accumulated amortization of $69,000 and $48,000 as of May 31, 2025 and 2024, respectively | 228,000 | 212,000 | 165,000 | 170,000 | 295,000 | |
| Other assets | 113,000 | 203,000 | 79,000 | 96,000 | 264,151 | |
| Total Assets | 6 | 9 | 14 | 11 | 12 | |
| Accounts payable and accrued expenses | 672,000 | 1 | 892,000 | 972,000 | 583,000 | |
| Accrued compensation | 655,000 | 655,000 | 696,000 | 647,000 | 388,896 | |
| Advances from customers | 55,000 | 85,000 | 60,000 | 51,000 | — | |
| Lease liabilities, current portion | 358,000 | 326,000 | 297,000 | 341,000 | 327,944 | |
| Total current liabilities | 2 | 2 | 2 | 2 | 1 | |
| Lease liabilities, net of current portion | 100,000 | 459,000 | 785,000 | 1 | 1 | |
| Total Liabilities | 2 | 3 | 3 | 3 | 3 | |
| Commitments and contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock, value | — | — | — | — | — | |
| Common stock, $0.08 par value, 3,125,000 shares authorized, 2,546,216 and 2,103,154 issued and outstanding at May 31, 2025 and May 31, 2024, respectively | 203,000 | 168,000 | 1 | 1 | 984,571 | |
| Additional paid-in capital | 57 | 55 | 53 | 42 | 39 | |
| Accumulated other comprehensive loss | −105,000 | −102,000 | −110,000 | −74,000 | −47,956 | |
| Accumulated deficit | −53 | −48 | −42 | −35 | −31 | |
| Total Shareholders Equity | 4 | 7 | 12 | 8 | 9 | |
| Total Liabilities and Shareholders Equity | 6 | 9 | 14 | 11 | 12 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-05-31 | FY 2024 2024-05-31 | FY 2023 2023-05-31 | FY 2022 2022-05-31 | FY 2021 2021-05-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 87,000 | 81,000 | 84,000 | 339,096 | 138,267 | |
| Provision (recovery) for allowance for credit losses | 8,000 | −10,000 | 342,000 | −684,000 | 766,434 | |
| Provision (recovery) for inventory reserves | 4,000 | −205,000 | −174,000 | −772,000 | 2 | |
| Share-based compensation | 460,000 | 837,000 | 1 | 1 | — | |
| Amortization of right-of-use asset | 313,000 | 293,000 | 267,000 | 256,000 | 237,588 | |
| Accounts receivable | 209,000 | −215,000 | −291,000 | 1 | −455,614 | |
| Inventories | 882,000 | −115,000 | 534,000 | 2 | −2 | |
| Prepaid expenses and other | −17,000 | 62,000 | 20,000 | 50,000 | 1 | |
| Other assets | 8,000 | −44,000 | 18,000 | 169,000 | −95,958 | |
| Accounts payable and accrued expenses | −466,000 | 246,000 | −80,000 | 389,000 | −403,331 | |
| Accrued compensation | 1,000 | −41,000 | 49,000 | 258,000 | 110,269 | |
| Advances from customers | −30,000 | 25,000 | 9,000 | 51,000 | — | |
| Reduction in lease liabilities | −327,000 | −297,000 | −297,000 | — | — | |
| Net cash used in operating activities | −4 | −5 | −5 | −479,000 | −5 | |
| Purchases of property and equipment | — | −51,000 | −64,000 | −57,000 | −135,856 | |
| Expenditures related to intangibles | −37,000 | −64,000 | −14,000 | −113,000 | −159,727 | |
| Net cash used in investing activities | −37,000 | −115,000 | −78,000 | −170,000 | −295,583 | |
| Gross proceeds from sale of common stock | 2 | — | 10 | 2 | 1 | |
| Deferred offering costs | −3,000 | −81,000 | — | — | — | |
| Costs from sale of common stock | −44,000 | — | −705,000 | −85,000 | −165,919 | |
| Proceeds from exercise of stock options | 15,000 | — | 81,000 | 77,000 | 102,255 | |
| Net cash provided by (used in) financing activities | 2 | −81,000 | 9 | 2 | 1 | |
| Effect of exchange rate changes in cash | −3,000 | 8,000 | −36,000 | −26,000 | −8,115 | |
| Net decrease in cash and cash equivalents | −2 | −6 | 4 | 2 | −4 | |
| Income taxes | 10,000 | 41,000 | 51,000 | 24,000 | — | |
| Deferred Offering Costs | 84,000 | — | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro